19026-73-4

Upstream product

• 19835-38-2 1-adamantylacetyl chloride 
• 4942-47-6 (adamant-1-yl)-acetic acid 
• 32132-59-5 2-((1R,3R,5R,7R)-adamantan-2-yl)acetyl chloride 
• 26082-22-4 adamantan-2-ylacetic acid 
• 16269-13-9 1-Carboxymethyladamantane nitrile 
• 75-05-8 acetonitrile 

Downstream Products

• 26482-53-1 2-(1-adamantyl)ethanamine 
• 16269-13-9 1-Carboxymethyladamantane nitrile 
• 23074-42-2 1-adamantanecarbonitrile 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATING RESPIRATORY DISEASE

Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: Formula (I), wherein (AA) represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are as defined herein; are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

Detection of biomolecules by sensitizer-linked substrates

Methods and compositions for detecting and characterizing target biomolecules using sensitizer-linked substrate molecules are disclosed. High throughput screening assays and therapeutic applications of the inventions are also included.

A facile and efficient one-pot synthesis of nitriles from carboxylic acids

Direct transformation of aliphatic carboxylic acids to the corresponding nitriles can be easily performed with acetonitrile in the presence of sulfuric acid. Georg Thieme Verlag Stuttgart.

Cycloalkylamides and their therapeutic applications

The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.

Cycloalkylamides and their therapeutic applications

The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.

Method for preparing some 1-adamantancecarboxamides

This invention relates to a method for the novel preparation of 1-adamantanecarboxamides and 1-adamantaneacetamides. Adamantanecarboxamides and adamantaneacetamides are prepared in high yields (80-100%) by treating adamantanecarboxylic acid and adamantaneacetic acid with N,N-diethyl-1,1,2,3,3,3-hexafluoropropylamine, followed by addition of aqueous ammonia or the appropriate amine. The procedure, carried out at ambient temperature using common laboratory equipment, is both convenient and rapid, requiring no more than one or two hours. Several reactions can be carried out simultaneously.

Synthesis and Reactions of Imidates Containing 1-Adamantyl Group

New unsubstituted and N-substituted 4-(1-adamantyl)benzimidates and (1-adamantyl)acetimidates were prepared from 1-adamantyl-substituted nitriles by a modified Pinner procedure.

Design of Inhibitors from the Three-Dimensional Structure of Alcohol Dehydrogenase. Chemical Synthesis and Enzymatic Properties

Inhibitors of liver alcohol dehydrogenase were designed from the three-dimensional structure of the enzyme.The ligand to the catalytic zinc ion is an amide group or, better, a formamide group.With the latter function, a hydrogen bond between the NH group and the hydroxyl group of Ser-48 may be formed.The hydrophobic substrate binding site brings structural restraints. α-ω bifunctional molecules show good inhibitory properties possibly due to the interactions with polar residues at the entrance of the substrate binding site.